Leonard Shultz to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications Leonard Shultz has written about TOR Serine-Threonine Kinases.
Connection Strength
0.343
-
Coate KC, Dai C, Singh A, Stanley J, Covington BA, Bradley A, Oladipupo F, Gong Y, Wisniewski S, Sellick K, Spears E, Poffenberger G, Schornack AMR, Bustabad A, Rodgers T, Dey N, Shultz LD, Greiner DL, Yan H, Powers AC, Chen W, Dean ED. Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners. Mol Metab. 2024 Dec; 90:102050.
Score: 0.220
-
Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, M?nkk?nen J, R?dini F, Heymann D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010 Dec 15; 70(24):10329-39.
Score: 0.083
-
Dai C, Walker JT, Shostak A, Padgett A, Spears E, Wisniewski S, Poffenberger G, Aramandla R, Dean ED, Prasad N, Levy SE, Greiner DL, Shultz LD, Bottino R, Powers AC. Tacrolimus- and sirolimus-induced human ? cell dysfunction is reversible and preventable. JCI Insight. 2020 01 16; 5(1).
Score: 0.040